EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alternative ergosterol biosynthetic pathways confer antifungal drug resistance in the human pathogens within the Mucor species complex

María Isabel Navarro-Mendoza iD, Carlos Pérez-Arques iD, Josie Parker iD, Ziyan Xu, Steven Kelly iD, Joseph Heitman iD

mBio · 14.08.2024 · 15 (8)

DOI: 10.1128/mbio.01661-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 14.08.2024. Verfasst von María Isabel Navarro-Mendoza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Ergosterol, Antifungal Agents, Drug Resistance, Fungal, Biosynthetic Pathways. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), Astellas | Astellas Pharma Global Development (Astellas Pharma Global Development, Inc.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucormycoses are emerging fungal infections caused by a variety of heterogeneous species within the Mucorales order. Among the Mucor species complex, Mucor circinelloides is the most frequently isolated pathogen in mucormycosis patients and despite its clinical significance, there is an absence of established genome manipulation techniques to conduct molecular pathogenesis studies. In this study, we generated a spontaneous uracil auxotrophic strain and developed a genetic transformation procedure to analyze molecular mechanisms conferring antifungal drug resistance. With this new model, phenotypic analyses of gene deletion mutants were conducted to define Erg3 and Erg6a as key biosynthetic enzymes in the M. circinelloides ergosterol pathway. Erg3 is a C-5 sterol desaturase involved in growth, sporulation, virulence, and azole susceptibility. In other fungal pathogens, erg3 mutations confer azole resistance because Erg3 catalyzes the production of a toxic diol upon azole exposure. Surprisingly, M. circinelloides produces only trace amounts of this toxic diol and yet, it is still susceptible to posaconazole and isavuconazole due to alterations in membrane sterol composition. These alterations are severely aggravated by erg3 Δ mutations, resulting in ergosterol depletion and, consequently, hypersusceptibility to azoles. We also identified Erg6a as the main C-24 sterol methyltransferase, whose activity may be partially rescued by the paralogs Erg6b and Erg6c. Loss of Erg6a function diverts ergosterol synthesis to the production of cholesta-type sterols, resulting in resistance to amphotericin B. Our findings suggest that mutations or epimutations causing loss of Erg6 function may arise during human infections, resulting in antifungal drug resistance to first-line treatments against mucormycosis. IMPORTANCE The Mucor species complex comprises a variety of opportunistic pathogens known to cause mucormycosis, a potentially lethal fungal infection with limited therapeutic options. The only effective first-line treatments against mucormycosis consist of liposomal formulations of amphotericin B and the triazoles posaconazole and isavuconazole, all of which target components within the ergosterol biosynthetic pathway. This study uncovered M. circinelloides Erg3 and Erg6a as key enzymes to produce ergosterol, a vital constituent of fungal membranes. Absence of any of those enzymes leads to decreased ergosterol and consequently, resistance to ergosterol-binding polyenes such as amphotericin B. Particularly, losing Erg6a function poses a higher threat as the ergosterol pathway is channeled into alternative sterols similar to cholesterol, which maintain membrane permeability. As a result, erg6a mutants survive within the host and disseminate the infection, indicating that Erg6a deficiency may arise during human infections and confer resistance to the most effective treatment against mucormycoses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErgosterolAntifungal AgentsDrug Resistance, FungalBiosynthetic PathwaysMucorHumansMucormycosisMicrobial Sensitivity TestsTriazolesFungal ProteinsGene DeletionNitrilesPyridinesOxidoreductases

Stichwörter der Autor:innen

Erg3Erg6Mucoralesantifungal resistanceergosterolfungigenetic tranformation

Substanzen

ErgosterolAntifungal Agentssterol delta-5 desaturaseTriazolesposaconazoleFungal ProteinsisavuconazoleNitrilesPyridinesOxidoreductases

Autor:innen und Institutionen

  • Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
  • Molecular Biosciences Division, School of Biosciences, Cardiff University, Cardiff, Wales, United Kingdom.
  • Institute of Life Science, Swansea University Medical School, Swansea, Wales, United Kingdom.

ORCID-Profile: María Isabel Navarro-Mendoza, Carlos Pérez-Arques, Josie Parker, Steven Kelly, Joseph Heitman

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • Astellas | Astellas Pharma Global Development (Astellas Pharma Global Development, Inc.)

Zitieren

APA

Navarro-Mendoza, M. I., Pérez-Arques, C., Parker, J., Xu, Z., Kelly, S., & Heitman, J. (2024). Alternative ergosterol biosynthetic pathways confer antifungal drug resistance in the human pathogens within the Mucor species complex. mBio, 15(8). https://doi.org/10.1128/mbio.01661-24

Vancouver

Navarro-Mendoza MI, Pérez-Arques C, Parker J, Xu Z, Kelly S, Heitman J. Alternative ergosterol biosynthetic pathways confer antifungal drug resistance in the human pathogens within the Mucor species complex. mBio. 2024;15(8). doi:10.1128/mbio.01661-24

BibTeX
@article{NavarroMendoza2024,
  author = {Navarro-Mendoza, María Isabel and Pérez-Arques, Carlos and Parker, Josie and Xu, Ziyan and Kelly, Steven and Heitman, Joseph},
  title = {Alternative ergosterol biosynthetic pathways confer antifungal drug resistance in the human pathogens within the Mucor species complex},
  journal = {mBio},
  year = {2024},
  volume = {15},
  number = {8},
  doi = {10.1128/mbio.01661-24}
}
Kostenlos starten →